Development of neutralizing antibodies is an important hindrance that limits repeated administration of adenoviral vectors for gene transfer. One way to avoid this problem would be to coat the virus with a substance that could shield it from antibodies. To develop such a system, we coated negatively-charged adenovirus with the cationic lipid GL-67 and included polyethylene glycol (PEG) in the complex as dioleoylphosphatidylethanolamine-PEG (DOPE-PEG). This complex enhanced gene transfer to cells that were difficult to infect both in vitro and in vivo. GL-67/DOPE-PEG coated the virus and prevented antibody binding. As a result, 50-fold higher concentrations of immune plasma were required for neutralization than with adenovirus alone. However, use of the complex provided no appreciable protection from neutralization when vector was delivered in vivo to immunized animals. These data are the first to suggest that formation of a complex around adenovirus can partially shield it from immune plasma in vitro. Despite the lack of protection in vivo, these results suggest the feasibility of developing a system in which the virus is effectively shielded from neutralizing antibodies and capable of repeat administration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/sj.gt.3300665 | DOI Listing |
Adv Biotechnol (Singap)
February 2024
CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200030, China.
Pichia pastoris is a popular yeast host for high-level heterologous expression of proteins on an industrial scale owing to its reliable expression, robust growth, high fermentation density, and easy genetic manipulation and cultivation at a relatively low cost. Of particular interest is its high secretion efficiency for small proteins including insulin, human serum albumin, vaccines, enzymes, and llama-derived heavy-chain only antibodies (nanobodies) for pharmaceutical and research applications. However, a recurring challenge in using P.
View Article and Find Full Text PDFAdv Biotechnol (Singap)
January 2024
Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200030, China.
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) Variants of Concern (VOCs), such as the Omicron sub-variants, present significant challenges in pandemic control due to their capacity to escape antibodies and breach vaccine protections. Discovering antibodies that can tolerate mutations in VOCs and understanding their underlying mechanisms is crucial for developing therapeutics for COVID-19 patients, particularly those for whom other therapies may be unsuitable. Here, we report the neutralization of the Omicron variant by FD20, a broadly active human monoclonal antibody.
View Article and Find Full Text PDFFront Vet Sci
January 2025
College of Veterinary Medicine, Henan Agricultural University, Zhengzhou, China.
Feline herpesvirus 1 (FHV-1) is an important pathogen causing infectious rhinotracheitis in felids, mainly infecting the upper respiratory tract and conjunctiva. Multiple vaccines are available to prevent FHV-1 infection, and the antibody levels are always used to evaluate their effectiveness. However, the cellular immunity response following immunization in cats remains unclear.
View Article and Find Full Text PDFNature
January 2025
Department of Mathematics & Computer Science, Freie Universität Berlin, Berlin, Germany.
Since the onset of the pandemic, many SARS-CoV-2 variants have emerged, exhibiting substantial evolution in the virus' spike protein, the main target of neutralizing antibodies. A plausible hypothesis proposes that the virus evolves to evade antibody-mediated neutralization (vaccine- or infection-induced) to maximize its ability to infect an immunologically experienced population. Because viral infection induces neutralizing antibodies, viral evolution may thus navigate on a dynamic immune landscape that is shaped by local infection history.
View Article and Find Full Text PDFJ Infect Public Health
January 2025
Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, Iran. Electronic address:
Background: Given the limited available data about to the number of vaccine doses administered over an extended time in Iran, the immune status of vaccinated individuals and any potential disparities in this regard among those who received different numbers of vaccine doses remain unknown. Therefore, this study aimed to assess humoral immunity of individuals who received different doses of the COVID-19 vaccines in Iran.
Methods: This study was conducted from February, 2022 to December 2023 including 605 vaccinated subjects.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!